Skip to content
Screener

Cash & Equivalents at other companies

Bristol-Myers Squibb logo
Bristol-Myers SquibbBMY
$8.72B-30.8%
Eli Lilly logo
Eli LillyLLY
$8.95B+165%
Johnson & Johnson logo
Johnson & JohnsonJNJ
$20.42B+9.9%
Amgen logo
AmgenAMGN
$574M+5.9%
AbbVie logo
AbbVieABBV
$9.39B+81.5%
MoonLake Immunotherapeutics logo
MoonLake ImmunotherapeuticsMLTX
$298.49M+9.9%

Other financials

Income statement

See full
Revenue-
Operating income-$36.4M-45.2%
Net income-$31.8M-51.5%
EPS (diluted)-$0.46+93.4%

Balance sheet

See full
Total debt$1.8M+90.8%
Total equity$486.7M+33.4%
Total assets$504.5M+33.8%

Cash flow

See full
Operating cash flow-$23.6M-13.0%
CapEx$73.0K+462%
Free cash flow-$23.7M-13.3%

Valuation

See full
Market cap$5.94B+1,017%
Enterprise value$5.89B+1,158%

Returns & leverage

See full
Return on equity-27.3%-11.1pp
Debt / equity0.0×
Current ratio23.8×-6.3×

Where this comes from

Reported directly by Oruka Therapeutics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents.

The source filing: Oruka Therapeutics, Inc.’s 10-Q, filed May 13, 2026.

Filed
May 13, 2026, 4:01 PM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0001213900-26-055769
Line itemThree Months Ended March 31, 2026Three Months Ended March 31, 2025
Proceeds from issuance of common stock upon exercise of stock options and employee warrants1,698
Proceeds from at-the-market offering, net of commissions38,902
Net cash provided by financing activities40,600
Net increase in cash and cash equivalents2,58521,997
Cash and cash equivalents at beginning of period46,93561,575
Cash and cash equivalents at end of period$49,520$83,572
Supplemental disclosures of non-cash financing activities:
Amounts receivable related to exercise of stock options and employee warrants$68

Item 1. Financial Statements (Unaudited)

FAQ

What is Oruka Therapeutics, Inc.'s cash & equivalents?
Oruka Therapeutics, Inc. (ORKA) reported cash & equivalents of $49.52M in Q1 2026.
How has Oruka Therapeutics, Inc.'s cash & equivalents changed year-over-year?
Oruka Therapeutics, Inc.'s cash & equivalents decreased by 40.7% year-over-year, from $83.57M to $49.52M.
What is the long-term trend for Oruka Therapeutics, Inc.'s cash & equivalents?
Over 5 years (2020 to 2025), Oruka Therapeutics, Inc.'s cash & equivalents has grown at a -0.9% compound annual growth rate (CAGR), from $49.07M to $46.94M.
What does cash & equivalents mean?
Cash on hand plus highly liquid investments with maturities of three months or less at purchase — treasury bills, money market funds, and commercial paper.

Ask your AI about Oruka Therapeutics, Inc.'s cash & equivalents.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude